Procarbazine

Summary

Procarbazine (CHEMBL1321) is an approved small-molecule antineoplastic agent (ATC L01XB01); indicated across 6 conditions including neoplasm and hodgkins lymphoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XB01
• Indications: 6 conditions
• Clinical trials: 64
• Chemistry: 221.3 Da · C12H19N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1321
Name	Procarbazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4915
ChEBI	CHEBI:71417
ATC	L01XB01
Molecular formula	C12H19N3O
Molecular weight	221.3
InChIKey	CPTBDICYNRMXFX-UHFFFAOYSA-N

SMILES: CC(C)NC(=O)C1=CC=C(C=C1)CNNC

IUPAC name: 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide

ChEBI definition: A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin’s lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.

Pharmacological roles (ChEBI): antineoplastic agent.

Also known as: Procarbacine, Procarbazina, Procarbazine, SID11112335, procarbazine, PROCARBAZINE, SID144212055, SID174007426, PROCARBAZINE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1200410, CHEMBL5715253

Patent coverage: 28,372 distinct patent families (117,257 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, Prostaglandin G/H synthase 2, Polyunsaturated fatty acid lipoxygenase ALOX15, Cytochrome P450 1A2, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.52	AC50	301	nM	CHEMBL_ACT_25173913
PTGS2	5.82	AC50	1500	nM	CHEMBL_ACT_25165715
CYP1A2	5.8	AC50	1585	nM	CHEMBL_ACT_6051570
LMNA	5.5	Potency	3162	nM	CHEMBL_ACT_3651545
CYP2C19	5.3	Potency	5012	nM	CHEMBL_ACT_4015416
CYP2C19	5.3	AC50	5012	nM	CHEMBL_ACT_6039804
ALOX15	5.1	Potency	7943	nM	CHEMBL_ACT_4466515

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
lymphoma	3	MONDO:0005062	EFO:0000574
central nervous system neoplasm	3	MONDO:0006130	EFO:1000158

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
glioblastoma	2	MONDO:0018177	EFO:0000519

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 64.

Phase distribution

Phase	Trials
PHASE2	32
PHASE3	21
Not specified	5
PHASE1/PHASE2	2
PHASE1	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002462	PHASE3	ACTIVE_NOT_RECRUITING	RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin’s Disease
NCT00379041	PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin’s Lymphoma
NCT00887146	PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT02661503	PHASE3	ACTIVE_NOT_RECRUITING	HD21 for Advanced Stages
NCT05675410	PHASE3	RECRUITING	A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT00002569	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
NCT00002840	PHASE3	COMPLETED	Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma
NCT00002944	PHASE3	COMPLETED	Combination Chemotherapy in Treating Children With Progressive Brain Tumors
NCT00003293	PHASE3	COMPLETED	SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
NCT00003375	PHASE2/PHASE3	COMPLETED	Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
NCT00003421	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Hodgkin’s Disease
NCT00003564	PHASE3	WITHDRAWN	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
NCT00003788	PHASE3	UNKNOWN	Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
NCT00049595	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin’s Lymphoma
NCT00052455	PHASE3	COMPLETED	Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
NCT00264953	PHASE3	COMPLETED	HD11 for Intermediate Stages
NCT00265031	PHASE3	COMPLETED	HD12 for Advanced Stages
NCT00433459	PHASE3	COMPLETED	Combination Chemotherapy in Treating Young Patients With Hodgkin’s Lymphoma
NCT00577993	PHASE3	COMPLETED	Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
NCT00678327	PHASE3	COMPLETED	Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
NCT01251107	PHASE3	COMPLETED	Study Comparing ABVD vs BEACOPP in Advanced Hodgkin’s Lymphoma
NCT01356680	PHASE3	COMPLETED	HD17 for Intermediate Stage Hodgkin Lymphoma
NCT05425654	PHASE2	RECRUITING	RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
NCT07015242	PHASE2	RECRUITING	A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT00002463	PHASE2	COMPLETED	Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
NCT00002806	PHASE2	COMPLETED	Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma
NCT00003101	PHASE2	COMPLETED	Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
NCT00003113	PHASE2	TERMINATED	Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin’s Lymphomas
NCT00003114	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin’s Disease
NCT00003929	PHASE2	WITHDRAWN	Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00004004	PHASE1/PHASE2	COMPLETED	Procarbazine in Treating Patients With Recurrent Brain Tumor
NCT00004010	PHASE2	COMPLETED	Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin’s Disease
NCT00025064	PHASE2	UNKNOWN	Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin’s Lymphoma
NCT00049439	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin’s Lymphoma
NCT00074191	PHASE2	COMPLETED	Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00079092	PHASE2	COMPLETED	Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00079105	PHASE2	COMPLETED	A Phase II Study VEPEMB In Patients With Hodgkin’s Lymphoma Aged ≥ 60 Years
NCT00284271	PHASE2	COMPLETED	Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
NCT00335140	PHASE2	TERMINATED	Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00416832	PHASE2	COMPLETED	Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin’s Lymphoma
NCT00503594	PHASE2	UNKNOWN	Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
NCT00574496	PHASE2	COMPLETED	Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
NCT00666484	PHASE2	COMPLETED	Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
NCT00822120	PHASE2	COMPLETED	S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
NCT00989352	PHASE2	UNKNOWN	Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
NCT01132807	PHASE2	COMPLETED	Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01390584	PHASE2	TERMINATED	Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01399372	PHASE2	COMPLETED	Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT01468740	PHASE2	UNKNOWN	Prospective Study on HIV-related Hodgkin Lymphoma
NCT01569204	PHASE2	COMPLETED	Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
NCT01737346	PHASE2	UNKNOWN	Procarbazine and Lomustine in Recurrent Glioblastoma
NCT01775475	PHASE2	COMPLETED	Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
NCT02298283	PHASE2	COMPLETED	Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
NCT02315326	PHASE1/PHASE2	COMPLETED	Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
NCT03495960	PHASE2	COMPLETED	Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
NCT05008224	PHASE2	COMPLETED	Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
NCT06541665	PHASE1	ACTIVE_NOT_RECRUITING	Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
NCT00005796	PHASE1	COMPLETED	Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
NCT00734773	EARLY_PHASE1	WITHDRAWN	Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
NCT00187057	Not specified	COMPLETED	Study for Treatment of Cancer in Children With Ataxia-telangiectasia
NCT00416377	Not specified	UNKNOWN	Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin’s Lymphoma
NCT00417014	Not specified	UNKNOWN	Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin’s Lymphoma
NCT00594815	Not specified	COMPLETED	Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT02333513	Not specified	UNKNOWN	A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).